

**Digital Mind**  
TECHNOLOGY



**Blackhawk  
Growth Corp.**

# Important Notice.

This Investor Presentation Document (IPD) dated 1 November 2021 is not a document lodged with ASIC.

This IPD, has been prepared by **Digital Mind Technology Pty Ltd**, a wholly owned subsidiary of Blackhawk Growth Corp (the "Company") for the purpose of providing certain financial and business information to potential investors.

This IPD is being provided to potential investors on the basis that they are a sophisticated investor or professional investor for the purposes of Section 708 of the Corporations Act. If you are not a sophisticated investor or professional investor for the purposes of Section 708 of the Corporations Act, any application that you make to acquire Shares in the Company will not be accepted by the Company unless the Company is otherwise satisfied you are a person to whom securities may be issued without disclosure under one of the other exemptions in Section 708 of the Corporations Act. In reading and accepting this IPD, the recipient agrees for itself and its related bodies corporate and their respective directors, officers, employees, agents, representatives and advisers (together the "Recipient") that it is provided on the terms and conditions of this important Notice.

You must provide a certificate certifying that you are a sophisticated investor or professional investor for the purposes of Section 708 of the Corporations Act (or evidence that you fall under one of the other exemptions in Section 708 of the Corporations Act) before any such application will be considered. A pro-forma certificate accompanies this IPD, and must be included with any application for Shares.

## Important Document

It is important that you carefully read this IPD in its entirety before deciding to invest in the Company and, in particular, that you consider the risk factors that could affect the financial performance of the Company and your investment in the Company. You should carefully consider these factors in light of your personal circumstances (including financial and taxation issues) and seek professional advice from your accountant, lawyer or other professional adviser before deciding whether to invest.

## No recommendation

This IPD is not to be considered as a recommendation by the Company or any of its directors, officers, employees, agents or advisers that any Recipient invest in the Company, or that this investment is a suitable investment for the Recipient. The Recipient should conduct and rely upon its own investigation and analysis of the information in this IPD and other matters that may be relevant to it in considering whether to invest. Each Recipient considering an investment must make, and will be taken to have made, its own independent investigation and analysis of the information in this IPD. Independent expert advice (including from a Recipient's accountant, lawyer or other professional adviser) should be sought before making a decision to invest.

## Distribution

This IPD is for selected recipients for purposes of Section 708 of the Corporations Act. It is provided on a strictly private and confidential basis to be used solely by the Recipient. It must not be made available to, or discussed with, any other person without the prior written consent of the Management Team. It is provided to the Recipient solely for its use in connection with providing background information in relation to the Company and the raising of capital and it is not to be used for any other purpose. The distribution of this IPD in jurisdictions outside Australia may be restricted by law and therefore persons into whose possession this IPD comes should seek advice on and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of those laws. This IPD does not constitute an offer of securities in any

jurisdiction where, or to any person to whom, it would be unlawful to issue this IPD.

## Disclaimer

This IPD and all information (whether in writing or otherwise) which may subsequently be made available to you (**Subsequent Information**) is provided on the terms and conditions set out in this "Important Notice" section. If the terms and conditions set out in this Important Information section are not acceptable to you, then this IPD and any Subsequent Information must be returned immediately to the Company. Retention of this IPD and any Subsequent Information will be deemed to constitute acceptance by you of the terms and conditions set out in this Important Notice section.

## No Representations

By submitting an application in response to this IPD, you are deemed to warrant and represent that you do not (and agree that you will not) rely on this IPD, including any forecasts, forward looking statements or prospective financial information contained in the IPD, any Subsequent Information, or any other statement, warranty, representation, express or implied, made by the Company or any of its officers, employees, agents, advisers, consultants or other representatives (**Representatives**) in connection with making a decision about whether or not to invest in the Company.

## No Responsibility for Contents of Investor Presentation Document

To the maximum extent permitted by law, no representation, warranty or undertaking, express or implied, is made and, to the maximum extent permitted by law, no responsibility or liability is accepted by any of its directors, officers, employees, agents, promoters or advisers or any other person as to the adequacy, accuracy, completeness or reasonableness of this IPD. To the maximum extent permitted by law, no responsibility for any errors or omissions from this IPD whether arising out of negligence or otherwise is accepted. This IPD contains various opinions, estimates and forecasts which are based upon assumptions which may not prove to be correct or appropriate. Except to the extent implied by law, no representation or warranty as to the validity, certainty or completeness of any of the assumptions or the accuracy of the information, opinions, estimates or forecasts contained in this IPD is made by the Website or any of its directors, officers, employees, agents or advisers.

## Accuracy of Projections and Forecasts

All projections and forecasts in this IPD are for illustrative purposes only using the assumptions described in this document. Actual results may be materially affected by changes in economic and other circumstances. The reliance that the Recipient places upon the projections and forecasts is a matter for its own commercial judgment. No representation or warranty is made that any projection, forecast, assumption or estimates contained in this IPD should or will be achieved.

## Forward Looking Statements

Any statements of opinion, belief, projections, forecasts or statements relating to expectations in this IPD that constitute statements relating to future acts, events and circumstances are for example only and do not assure the current or future performance of the Company. The Company offers no assurance or guarantee or warranty that those acts, events and circumstances will occur or arise in the manner in which they are portrayed in this document, and investors must be aware that they may not occur or arise in the way in which they are portrayed. No representation is made or assurance given that such statements, views, projections or forecasts are reasonable or correct.



# Highlights.



- ✓ A clinical trial stage company developing digital interventions to treat mental health conditions.
- ✓ Successfully completed a pilot randomized controlled trial with 69 patients of an online mindfulness-based program for people diagnosed with melanoma.
- ✓ <https://www.researchgate.net/publication/329333517> A pilot randomized controlled trial of an online mindfulness-based program for people diagnosed with melanoma
- ✓ Fully developed clinical trial protocol created by leading scientist at a major Australian University.
- ✓ Fully funded for Phase 1 clinical trials of mindfulness-based digital programs for people requiring pain management to avoid or reduce impact on mental health conditions.
- ✓ Clinical trials to be fully FDA compliant.
- ✓ World Class Research Team.
- ✓ Fully funded, approx. AUD\$2.5M cash at bank.



Blackhawk  
Growth Corp.

[digitalmindtechnology.com](https://digitalmindtechnology.com)



# Overview.



- Digital Mind Technology is pioneering research into the clinical use of mindfulness-based digital programs for people with chronic pain. Ineffective pain management is a leading cause of mental health conditions.
- Leading scientist Dr Russell has developed a clinical protocol and ran a successful pilot trial of 69 patients at a leading University for people diagnosed with melanoma.
- The study found that the intervention has the potential to help survivors cope with emotional difficulties by reducing stress and anxiety.
- Dr Russell has published extensively and has transferred her intellectual property including the data from the clinical pilot trial to Digital Mind Technology.
- The intellectual property will be used to run a Phase 1 clinical trial for patients suffering from chronic pain.
- The Phase 1 clinical trial is fully funded and will cost \$830,000. The trial will start in early 2022 and is expected to be completed by the end of 2022.
- The trial will be fully FDA compliant.

**Digital Mind Technology is working to develop digital platforms (Mobile, Smart Watch, and Web) that provides clinically proven mindfulness-based digital programs to help patients to deal with pain. These clinical programs have the potential to be provided to patients via health professionals in a clinical setting.**





# High Level Results of Pilot Clinical Trial.

- Study completion participants shows high participant retention using DMT's digital therapeutic model. Program adherence and usability of the technology is a major factor in the success of the intervention.
- The intervention was found helpful by 72% of respondents.
- The clinical trial illustrated statistically significantly reduced severity of emotional "fear" of cancer recurrence in this self guided intervention for substantially better emotional outcomes.
- The clinical results to date are encouraging for DMT's clinical trials in late stage cancer patients, targeting pain and mood disorders and DMT's aim to create a medical application for prescription in various patient groups.

<https://www.researchgate.net/publication/329333517> A pilot randomized controlled trial of an online mindfulness-based program for people diagnosed with melanoma






# Digital Interventions for better mental health.

Digital Mind Technology provides evidence-based digital interventions and conducts clinical trials of technology for use in mobile, desktop and wearables to reduce the risk of depression and anxiety in vulnerable groups.





# Evidence-based Mental Health Interventions.



Our evidence based clinical research aims to use clinical protocols that will comply with funding guidelines so that doctors can prescribe our digital based health programs to patients under a government and medical prescription funding model.

## At home and mobile mental health care

Mental health treatments traditionally involve medications and psychotherapies with a psycho-therapist. DMT fills an important gap between therapeutic sessions and doctor's visits, by delivering activities, thoughts and repertoires that are clinically proven to improve mental well being.




[digitalmindtechnology.com](https://digitalmindtechnology.com)

# Prescription medical technology in every patient's hands.

Mindfulness activities *developed from robust clinical trials* can be delivered using mobile and desktop applications and wearable devices.

By way of example a patient, wearing a fitbit or any other connected device that can sense heart rate and blood pressure, could be reminded to stop and take a breath, with interventions triggered by these biometric markers and signals and these interventions are clinically proven in DMT's therapeutic models.

Evidence-based intervention at the exact time a patient needs it could help reduce mental illness.





Digital Mind Technology is operating in a high growth sector:

**Funding for technology companies that are developing applications to treat behavioural, mental and brain health exceeded \$5.3 Billion to Q3 in 2021.**

*There is high demand for scalable mental health treatments using technology on mobile and online devices*

(Source: Global Institute of Mental & Brain Health Investment 2021)

# Valuations: Behavior, Mental and Brain Health Technology Companies.



Company	Description	Valuation at last funding (USD)
<b>Lyra</b>	Developer of a platform that offers teletherapy, telecoaching & digital self care tools	\$4.6B
<b>Calm</b>	Meditation App	\$2B
<b>Therapy Brands</b>	Software and services created for mental health treatments	\$1.2B
<b>Modern Health</b>	Developer of a mental wellness platform intended to help companies manage their employee's health benefits	\$1.17B
<b>Ginger</b>	Developer of a virtual healthcare platform designed to provide on-demand mental health support	\$1.1B
<b>MindMaze</b>	VR for neurorehabilitation	\$1.1B
<b>Cerebral</b>	Mental telehealth and wellness platform for employers	\$1B
<b>Headway</b>	Software enabled therapist network that onboards practices into insurance networks	\$770m
<b>Viz.ai</b>	Medical imaging technology platform that communicates time-sensitive information about stroke patients directly to clinicians	\$641m
<b>Workin Health</b>	Online Addiction recovery program	\$500m
<b>Happify Health</b>	Software-enabled healthcare platform developing digital therapeutics	\$435m



# Financing in behavioural & mental health technology is on the rise.



✓ Digital Mind Technology is developing its product from results of FDA approved Clinical Research

## Lyra

Recent Funding  
**\$200 million.**  
\$4.6B Valuation.



Recent Funding  
**\$75 million.**  
\$2B Valuation.

## ginger

Recent Funding  
**\$100 million.**  
\$1.1B Valuation.

## Cerebral

Recent Funding  
**\$127 million.**  
\$1B Valuation.

## elemy

Recent Funding  
**\$219 million.**  
\$1.15B Valuation.

## mindmaze

Recent Funding  
**\$125 million.**  
\$1.1B Valuation.

## Headway

Recent Funding  
**\$70 million.**  
\$770m Valuation.

## Workit Health

Recent Funding  
**\$118 million.**  
\$500m Valuation.

# Team.



## **Dr Lahiru Russell. Founder.**

MSc, PhD.

After graduating with a Master in Biochemistry from the University of Geneva, Switzerland, Dr Russell worked for a decade in the pharmaceutical industry managing clinical trials. Over the years Dr Russell developed an interest in the psychosocial adaptation to illness and strategies to manage the stress-related aspects of disease. Her studies in Epidemiology at the London School of Hygiene and Tropical Medicine (UK) stimulated her desire to undertake research in this field. Following this, Dr Russell joined the psycho-oncology research team at the Peter MacCallum Cancer Centre in Melbourne, Australia, evaluating supportive care interventions for people affected by cancer.

In 2018 Dr Russell was awarded her PhD from Deakin University, Australia. Coupling with her personal interest in mindfulness practices and her professional experience in psycho-oncology, Dr Russell's PhD research was designed to determine whether a mindfulness program could benefit people with melanoma. The focus of the program was to empower participants to manage their health by promoting awareness of emotions and teaching skills to manage distressing thoughts.

Dr Russell's vision is to empower people to engage in healthy self-care strategies to manage the impact of their illness for long-term wellbeing.

# Team.



## **Dr Zena Burgess. Strategy Advisor**

PhD. FAICD, FAPS. MBA

Zena has a strong interest in futures of health care. She serves as Director of MindBio Therapeutics, a clinical stage pharmaceutical company researching the use of emerging pharmaceuticals to treat mental health conditions and is a member of the international advisory board of Connex2MyDoctor and the telehealth influencers alliance. Dr Burgess is also a director of the Australian Patients Association and Chair of the board subcommittee on governance and risk of the Victorian Farmers Federation and is currently the Chief Executive Officer of the Australian Psychologists Society.

Formerly, Dr Burgess was Chief Executive of the Royal Australian College of General Practitioners. Zena has substantial experience serving on boards of government entities. She holds a PhD in psychology from the Australian Catholic University and a Master of Business Administration from Monash University and a Master of Education from La Trobe University. She has a wealth of experience in health changes and strategic advocacy to governments.





# Contact Us.

**Frederick Pels, Chief Executive Officer**

**Phone: (403)-991-7737**

**Email: [fred@blackhawkgrowth.com](mailto:fred@blackhawkgrowth.com)**

CSE: BLR | Frankfurt: OJJ0

[digitalmindtechnology.com](http://digitalmindtechnology.com)



**Annex.**

InvestmentPitch  
MEDIA



zoom



**ASHTON ADDISON**  
InvestmentPitch Media



**Dr LAHIRU RUSSELL PhD**  
Chief Scientist & Founder



[Dr Lahiru Russell on Investment Pitch - click here to watch](#)



digitalmindtechnology.com



# Intellectual Property and Published Works.



Russell, L., Whiffen, R., Chapman, L., Just, J., Dean, E., Ugalde, A. and White, S., 2021. **Hospital staff perspectives on the provision of smoking cessation care: a qualitative description study.** *BMJ open*, 11(5), p.e044489. DOI: 10.1136/bmjopen-2020-044489

Lynch, F.A.; Katona, L.; Jefford, M.; Smith, A.B.; Shaw, J.; Dhillon, H.M.; Ellen, S.; Phipps-Nelson, J.; Lai-Kwon, J.; Milne, D.; Russell, L.; Dax, V.; Diggins, J.; Kent, H.; Button-Sloan, A.; Elliott, J.; Shackleton, M.; Burrridge, H.; Ftanou, M. **Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma.** *J. Clin. Med.* 2020, 9, 2969. DOI: 10.3390/jcm9092969

Russell, L., McIntosh, R., Martin, C., Scott J., Kheng Soo W., Zappa B., Haynes K., Livingston PM. & Ugalde, A. **A model of cancer survivorship care within a community health setting: the Good Life Cancer Survivorship program.** *Journal of Cancer Survivorship.* 2019 DOI: 10.1007/s11764-019-00821-6

Russell, L., Ugalde, A., White, V., Pitcher, M., Jorgensen, S., Whitfield, K., ... & Livingston, P. **Relevance of mindfulness practices for Culturally And Linguistically Diverse cancer populations.** *Psycho-Oncology*, 2019 DOI: 10.1002/pon.5221

Ugalde A, Haynes K, White V, Russell L, Livingston PM. **"An Ambition to Make People Feel at Home" or "The Emperor's New Clothes"? Professional Stakeholder Views of Wellness Centres in Cancer Care.** *European Journal of Cancer Care.* 2019 DOI: 10.1111/ecc.13096

Russell L, Pascoe MC, Seymour JF, Aranda S, Butow P, Gough K, Schofield P. **The trials and tribulations of conducting an m-health pilot randomized controlled trial to improve oral cancer therapy adherence: recommendations for future multisite, non-drug clinical trials.** *BMC research notes.* 2019 Dec;12(1):226.

Russell L, Ugalde A, Orellana L, Milne D, Krishnasamy M, Chambers C, Austin D and Livingston P M, **A pilot randomised controlled trial of an online mindfulness-based program for people diagnosed with melanoma,** *Journal of Supportive Care in Cancer.* 2018 DOI: 10.1007/s00520-018-4574-6

Russell L, Ugalde A, Milne D, Austin D and Livingston P M, **Digital Characteristics and Dissemination Indicators to Optimize Delivery of Internet-Supported Mindfulness-Based Interventions for People With a Chronic Condition: Systematic Review,** *JMIR Mental Health.* 2018 DOI: 10.2196/mental.9645

Russell L, Ugalde A, Milne D, Krishnasamy M, Chung Seul O E, Austin D, Chambers R, Orellana L, and Livingston PM, **Feasibility of an online mindfulness-based program for patients with melanoma: study protocol for a randomised controlled trial,** *Trials.* 2018 Dec; 19(1):223

Pereira-Salgado A, Westwood JA, Russell L, Ugalde A, Ortlepp B, Seymour JF, Butow P, Cavedon L, Ong K, Aranda S, Breen S.,... & Schofield P, **Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment,** *JMIR mHealth and uHealth.* 2017. DOI: 10.2196/mhealth.8349

Russell L, Orellana L, Ugalde A, Milne D, Krishnasamy M, Chambers R, Livingston PM., **Exploring Knowledge, Attitudes, and Practice Associated With Meditation Among Patients With Melanoma, Integrative Cancer Therapies,** 2017. DOI: 10.1177/1534735417699514

Jefford M, Gough K, Drosdowsky A, Russell L, Aranda S, Butow P, Phipps-Nelson J, Young J, Krishnasamy M, Ugalde A, King D., ... and Schofield P, **A Randomized Controlled Trial of a Nurse-Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer,** *Oncologist,* 2016. DOI: 10.1634/theoncologist.2015-0533

Russell L, Gough K, Drosdowsky A, Schofield P, Aranda S, Butow PN, Westwood JA, Krishnasamy M, Young JM, Phipps-Nelson J, King D. & Jefford M, , **Psychological distress, quality of life, symptoms and unmet needs of colorectal cancer survivors near the end of treatment,** *Journal of Cancer Survivorship,* 2015. DOI: 10.1007/s11764-014-0422-y

Jefford M, Mann GB, Nolte L, Russell L, Brennan M., **Follow-up of Women with Early Stage Breast Cancer.** *Current Breast Cancer Reports,* 2014. DOI:10.1007/s12609-014-0150-3

Jefford M, Aranda S, Gough K, Lotfi-Jam K, Butow P, Krishnasamy M, Young J, Phipps-Nelson J, Russell L, King D, Schofield P., **Evaluating a nurse-led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial,** *Trials* 2013. DOI: 10.1186/1745-6215-14-260

